Identifying Hypercortisolism in Patients with Resistant Diabetes - Episode 3

Barriers to Accessing New Anti-Diabetes Medications

Published on: April 29, 2024

Hanford Yau, MD , Ralph DeFronzo, MD , Pam Kushner, MD , Honey East, MD, Christopher Lucci, MD

Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.

EP. 1: Defining Resistant Diabetes

EP. 2: Differentiating Medication Non-Adherence From Underlying Comorbidities

Now Viewing

EP. 3: Barriers to Accessing New Anti-Diabetes Medications

EP. 4: Suspecting Hypercortisolism in Patients With Resistant Diabetes

EP. 5: Testing for Hypercortisolism

EP. 6: Patient Subgroups With a Higher Prevalence of Hypercortisolism

EP. 7: Evolving Perception of Autonomous Adrenal Hypercortisolism

EP. 8: Pathophysiology of Hypercortisolism

EP. 9: Need to Address Underlying Hypercortisolism

EP. 10: Approaching Treatment in Hypercortisolism

EP. 11: Choosing Between Medical and Surgical Options for Hypercortisolism

EP. 12: Long-Term Outcomes for Patients Treated for Hypercortisolism